Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: Evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions

Brain Research

Volumn 856, Issue 1-2, 2000, Pages 227-235

  Crain, Stanley M ^a   Shen, Ke Fei ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antinociceptive tail flick assay; Excitatory opioid receptor function; GM1 ganglioside; Morphine tolerance; Mouse strain 129 SvEv; Naltrexone

Indexed keywords

GANGLIOSIDE GM1; MORPHINE; NALTREXONE; OPIATE RECEPTOR;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TAIL FLICK TEST;

ANIMALS; DRUG TOLERANCE; G(M1) GANGLIOSIDE; MALE; MICE; MICE, INBRED STRAINS; MORPHINE; NALTREXONE; RECEPTORS, OPIOID; TIME FACTORS;

EID: 0033953224     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02446-4     Document Type: Article

References (48)

1. G.K. Aghajanian, Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine, Nature 276 (1978) 186-188.
2. E.J. Bilsky, E.R. Castro, M. Ibrahim, T.P. Malan, F. Porreca, Sustained morphine exposure results in elevated dynorphin content in the lumbar/sacral spinal cord of ICR, but not 129 SvEv, mice: possible role in opioid antinociceptive tolerance, Internat. Narcot. Res. Conf., Proc. (1999) 45.
3. M.J. Christie, J.T. Williams, P.B. Osborne, C.E. Bellchambers, Where is the locus in opioid withdrawal?, Trends Pharmacol. Sci. 18 (1997) 134-140.
4. S.M. Crain, K.-F. Shen, After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition, J. Pharmacol. Exp. Ther. 260 (1992) 182-186.
5. S.M. Crain, K.-F. Shen, After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside, Brain Res. 575 (1992) 13-24.
6. S.M. Grain, K.-F. Shen, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment, Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10540-10544.
7. S.M. Grain, K.-F. Shen, Chronic morphine-treated sensory ganglion neurons remain supersensitive to the excitatory effects of naloxone for months after return to normal culture medium: an in vitro model of "protracted opioid dependence", Brain Res. 694 (1995) 103-110.
8. S.M. Grain, K.-F. Shen, GM1 ganglioside-induced modulation of opioid receptor-mediated functions, Ann. NY Acad. Sci. 845 (1998) 106-125.
9. S.M. Crain, K.-F. Shen, Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions, Trends Pharmacol. Sci. 19 (1998) 358-365.
10. S.M. Crain, K.-F. Shen, Antagonists of excitatory opioid receptor functions enhance morphine analgesic potency and attenuate opioid tolerance/dependence liability, Pain 84 (2000) in press.
11. G. Dawson, R.W. McLawhon, M.A. Scheideler, The mechanism of action of opiates and other neuroactive agents, in: S.E. Pfeiffer (Ed.), Application of Tissue Culture to Neurobiology, CRC Press, Boca Raton, FL, 1980, pp. 89-114.
12. K. Elliott, N. Minami, Y.A. Kolesnikov, G.W. Pasternak, C.E. Inturrisi, The NMDA receptor antagonists LY274614 and MK-801, and the nitric oxide synthase inhibitor NG-intro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids, Pain 56 (1994) 69-75.
13. K. Elliott, B. Kest, A. Man, B. Kao, C.E. Inturrisi, N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development, Neuropsychopharmacology 13 (1995) 347-356.
14. G.I. Elmer, J.D. Pieper, S.S. Negus, J.H. Woods, Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests, Pain 75 (1998) 129-140.
15. T.J. Gan, B. Ginsberg, P.S.A. Glass, J. Fortney, R. Jhaveri, R. Perno, Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate, Anesthesiology 87 (1997) 1075-1081.
16. E.F. Hahn, J. Fishman, R.D. Heilman, Narcotic antagonists: 4. Carbon-6 derivatives of n-substituted noroxymorphones as narcotic antagonists, J. Med. Chem. 18 (1975) 259-262.
17. J.S. Heyman, S.A. Mulvaney, H.I. Mosberg, F. Porreca, Opioid 5 receptor involvement in supraspinal and spinal antinociception in mice, Brain Res. 420 (1987) 100-108.
18. R. Iyengar, Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases, FASEB J. 7 (1993) 768-775.
19. G.P. Joshi, J. Duffy, J. Chehade, J. Wesevich, N. Gajraj, E.R. Johnson, Effects of prophylactic nalmefene on the incidence of morphine related side effects in patients receiving intravenous patient-controlled analgesia, Anesthesiology 90 (1999) 1007-1011.
20. Y. Kolesnikov, S. Jain, R. Wilson, G.W. Pasternak, Lack of morphine and enkephalin tolerance in 129/SvEv mice: evidence for a NMDA receptor defect, J. Pharmacol. Exp. Ther. 284 (1998) 455-459.
21. B.H. Manning, J. Mao, H. Frenk, D.D. Price, D.J. Mayer, Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance, Pain 67 (1996) 79-88.
22. D.J. Mayer, J. Mao, D.D. Price, The development of morphine tolerance and dependence is associated with translocation of protein kinase C, Pain 61 (1995) 365-374.
23. R.W. McLawhon, G.S. Schoon, G. Dawson, Glycolipids and opiate action, Eur. J. Cell Biol. 25 (1981) 353-358.
24. J.S. Mogil, J.E. Grisel, Transgenic studies of pain, Pain 77 (1998) 107-128.
25. J.S. Mogil, S.G. Wilson, Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies, Eur. J. Pain 1 (1997) 293-297.
26. J.S. Mogil, C.A. Lichtensteiger, S.G. Wilson, The effect of genotype on sensitivity to inflammatory nociception: characterization of resistant (A/J) and sensitive (C57BL/6J) inbred mouse strains, Pain 76 (1998) 115-125.
27. J.S. Mogil, S.G. Wilson, K. Bon, S.E. Lee, K. Chung, P. Raber, J.O. Pieper, H.S. Hain, J.K. Belknap, L. Hubert, G.I. Elmer, J.M. Chung, M. Devor, Heritability of nociception I: Responses of 11 inbred mouse strains on 12 measures of nociception, Pain 80 (1999) 67-82.
28. G.W. Pasternak, Pharmacological mechanisms of opioid analgesics, Clin. Neuropharmacol. 16 (1993) 1-18.
29. C.G. Pick, D. Paul, G.W. Pasternak, Comparison of naloxonazine and beta-funaltrexamine antagonism of mu 1 and mu 2 opioid actions, Life Sci. 48 (1991) 2005-2011.
30. R.K. Portenoy, R. Payne, Acute and chronic pain, in: J.H. Lowinson, P. Ruiz, R.B. Millman, J.G. Langrod (Eds.), Substance Abuse: A Comprehensive Textbook, 3rd edn., Williams and Wilkins, Baltimore, 1997, pp. 563-589.
31. M.A. Scheideier, G. Dawson, Direct demonstration of the activation of UDP-N-acetylgalactosamine:[GM3]N-acetylgalactosaminyltransferase by cyclic AMP, J. Neurochem. 46 (1986) 1639-1643.
32. K.-F. Shen, S.M. Crain, Cholera toxin-B blocks opioid excitatory effects on sensory neuron action potentials indicating that GM-1 ganglioside may regulate Gs-linked opioid receptor functions, Brain Res. 531 (1990) 1-7.
33. K.-F. Shen, S.M. Crain, Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid "dependence" without tolerance, Brain Res. 597 (1992) 74-83.
34. K.-F. Shen, S.M. Grain, Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence, Brain Res. 636 (1994) 286-297.
35. K.-F. Shen, S.M. Grain, Specific N- or C-terminus modified dynorphin and β-endorphin peptides can selectively block functions in sensory neurons and unmask potent inhibitory effects of opioid agonists, Brain Res. 673 (1995) 30-38.
36. K.-F. Shen, S.M. Grain, Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice, Brain Res. 757 (1997) 176-190.
37. K.-F. Shen, S.M. Crain, R.W. Ledeen, Brief treatment of sensory ganglion neurons with GM1 ganglioside enhances the efficacy of opioid excitatory effects on the action potential, Brain Res. 550 (1991) 130-138.
38. H. Suarez-Roca, W. Maixner, Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices, J. Pharmacol. Exp. Ther. 264 (1993) 648-653.
39. R.J. Tallarida, R.B. Murray, Manual of Pharmacologic Calculations with Computer Programs, 2nd edn., Springer, New York, 1986.
40. R.Z. Terwilliger, X.G. Ortiz, E.J. Nestler, Chronic morphine adminisration increases β-adrenergic receptor kinase (βARK) levels in the rat locus coeruleus, J. Neurochem. 63 (1994) 1983-1986.
41. P.J. Tiseo, C.E. Inturrisi, Attenuation and reversal of morphine tolerance by the competitive A'-methyl-D-aspartate receptor antagonist, LY2746614, J. Pharmacol. Exp. Ther. 264 (1993) 1090-1096.
42. K.A. Trujillo, H. Akil, Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801, Science 251 (1991) 85-87.
43. G.R. Uhl, I. Sora, Z. Wang, The μ, opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses, Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7752-7755.
44. E.L. Way, H.H. Loh, F.-H. Shen, Simultaneous quantitative assessment of morphine tolerance and physical dependence, J. Pharmacol. Exp. Ther. 167 (1969) 1-8.
45. G. Wu, Z.-H. Lu, R.W. Ledeen, GM1 ganglioside modulates prostaglandin El stimulated adenylyl cyclase in neuro-2A cells, Glycoconjugate J. 13 (1996) 235-239.
46. G. Wu, Z.-H. Lu, R.W. Ledeen, Interaction of 8-opioid receptor with GM1 ganglioside: conversion from inhibitory to excitatory mode, Mol. Brain Res. 44 (1997) 341-346.
47. G. Wu, Z.-H. Lu, J.W. Tzongjer, R.D. Howells, K. Christoffers, R.W. Ledeen, The role of GM1 ganglioside in regulating excitatory opioid effects, Ann. NY Acad. Sci. 845 (1998) 126-138.
48. I. Yano, A.E. Takemori, Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine, Res. Commun. Chem. Pathol. Pharmacol. 16 (1977) 721-734.